MAPT and supranuclear palsy, progressive, 1: For PSP, Tau aggregates alone can differentiate between PSP and normal control group similar to pTau, and the combination of the biomarkers improves the specificity and AUC, which underlines the role of Tau aggregates in PSP as possible biomarker.